Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 29 08 2020
revised: 01 10 2020
accepted: 20 10 2020
pubmed: 11 11 2020
medline: 14 4 2022
entrez: 10 11 2020
Statut: ppublish

Résumé

The value of a complete response to immune checkpoint inhibitor treatment for urothelial cancer is well recognised, but less is known about long-term outcomes in patients with a partial response or the benefit of achieving disease stabilisation. To determine clinical outcomes in patients with a partial response or stable disease on atezolizumab therapy for advanced urinary tract carcinoma (UTC). Data were extracted from three prospective trials (IMvigor210 cohort 2, SAUL, and IMvigor211) evaluating single-agent atezolizumab therapy for platinum-pretreated advanced UTC. The analysis population included 604 atezolizumab-treated and 208 chemotherapy-treated patients (229 achieving a partial response and 583 achieving stable disease). Atezolizumab 1200 mg every 3 wk until progression or unacceptable toxicity or single-agent chemotherapy for patients in the control arm of IMvigor211. Baseline characteristics, treatment exposure, overall survival, duration of disease control. Partial response and stable disease populations were analysed separately. The population of patients with a partial response included more patients with programmed cell death ligand 1 (PD-L1) expression on ≥5% of tumour-infiltrating immune cells than the stable disease population. The median time to best response was 2.1 mo across trials and treatments, regardless of the type of response. Atezolizumab-treated patients with a partial response had sustained disease control (median overall survival not reached); durations of disease control and overall survival were longer with atezolizumab than with chemotherapy. In patients with stable disease, median overall survival was numerically longer with atezolizumab (exceeding 1 yr) than with chemotherapy. Irrespective of treatment, durations of disease control and survival were shorter in patients with stable disease than in those achieving a partial response. These analyses are limited by their post hoc exploratory nature and relatively short follow-up. Stable disease and partial response are meaningful clinical outcomes in atezolizumab-treated patients with advanced UTC. In this report, we looked at the outcomes in patients whose tumours responded to treatment to some extent, but the tumour did not disappear completely. We aimed to understand whether a modest response to treatment was associated with meaningful long-term outcomes for patients. We found that on average, life expectancy was >1 yr in patients whose disease was stabilised and even longer in those whose tumours showed some shrinkage in response to treatment.

Sections du résumé

BACKGROUND BACKGROUND
The value of a complete response to immune checkpoint inhibitor treatment for urothelial cancer is well recognised, but less is known about long-term outcomes in patients with a partial response or the benefit of achieving disease stabilisation.
OBJECTIVE OBJECTIVE
To determine clinical outcomes in patients with a partial response or stable disease on atezolizumab therapy for advanced urinary tract carcinoma (UTC).
DESIGN, SETTING, AND PARTICIPANTS METHODS
Data were extracted from three prospective trials (IMvigor210 cohort 2, SAUL, and IMvigor211) evaluating single-agent atezolizumab therapy for platinum-pretreated advanced UTC. The analysis population included 604 atezolizumab-treated and 208 chemotherapy-treated patients (229 achieving a partial response and 583 achieving stable disease).
INTERVENTION METHODS
Atezolizumab 1200 mg every 3 wk until progression or unacceptable toxicity or single-agent chemotherapy for patients in the control arm of IMvigor211.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
Baseline characteristics, treatment exposure, overall survival, duration of disease control. Partial response and stable disease populations were analysed separately.
RESULTS AND LIMITATIONS CONCLUSIONS
The population of patients with a partial response included more patients with programmed cell death ligand 1 (PD-L1) expression on ≥5% of tumour-infiltrating immune cells than the stable disease population. The median time to best response was 2.1 mo across trials and treatments, regardless of the type of response. Atezolizumab-treated patients with a partial response had sustained disease control (median overall survival not reached); durations of disease control and overall survival were longer with atezolizumab than with chemotherapy. In patients with stable disease, median overall survival was numerically longer with atezolizumab (exceeding 1 yr) than with chemotherapy. Irrespective of treatment, durations of disease control and survival were shorter in patients with stable disease than in those achieving a partial response. These analyses are limited by their post hoc exploratory nature and relatively short follow-up.
CONCLUSIONS CONCLUSIONS
Stable disease and partial response are meaningful clinical outcomes in atezolizumab-treated patients with advanced UTC.
PATIENT SUMMARY RESULTS
In this report, we looked at the outcomes in patients whose tumours responded to treatment to some extent, but the tumour did not disappear completely. We aimed to understand whether a modest response to treatment was associated with meaningful long-term outcomes for patients. We found that on average, life expectancy was >1 yr in patients whose disease was stabilised and even longer in those whose tumours showed some shrinkage in response to treatment.

Identifiants

pubmed: 33168461
pii: S2405-4569(20)30293-5
doi: 10.1016/j.euf.2020.10.009
pmc: PMC9437861
mid: NIHMS1828689
pii:
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
atezolizumab 52CMI0WC3Y

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1084-1091

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Références

Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
Lancet Oncol. 2016 Nov;17(11):1590-1598
pubmed: 27733243
J Immunother Cancer. 2019 Mar 12;7(1):71
pubmed: 30867071
Clin Genitourin Cancer. 2020 Oct;18(5):351-360.e3
pubmed: 32146152
Eur Urol. 2019 Jul;76(1):73-81
pubmed: 30910346
World J Urol. 2019 Sep;37(9):1773-1784
pubmed: 30374610
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060

Auteurs

Jens Bedke (J)

Department of Urology, University of Tübingen, Tübingen, Germany. Electronic address: jens.bedke@med.uni-tuebingen.de.

Axel S Merseburger (AS)

Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Yohann Loriot (Y)

Department of Cancer Medicine and Institut National de la Santé et de la Recherche Médicale (INSERM) U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.

Daniel Castellano (D)

Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.

Ernest Choy (E)

CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Ignacio Duran (I)

Hospital Universitario Virgen del Rocio, Seville, Spain.

Jonathan E Rosenberg (JE)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Daniel P Petrylak (DP)

Smilow Cancer Center, Yale University, New Haven, CT, USA.

Robert Dreicer (R)

University of Virginia Cancer Center, Charlottesville, VA, USA.

Jose L Perez-Gracia (JL)

Clínica Universidad de Navarra, University of Navarra, Pamplona, Navarre, Spain.

Jean H Hoffman-Censits (JH)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

Michiel S Van Der Heijden (MS)

The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Julie Pavlova (J)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Lars Thiebach (L)

Roche Pharma AG, Grenzach-Wyhlen, Germany.

Sabine de Ducla (S)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Simon Fear (S)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Thomas Powles (T)

Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, UK.

Cora N Sternberg (CN)

San Camillo and Forlanini Hospitals, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH